(Q39562000)

13 September 2017

title

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes (English)

1 reference

13 September 2017

1 reference

6

Gerd Fätkenheuer

1 reference

13 September 2017

2

Nadine Lübke

0 references

Rolf Kaiser

9

object named as

Rolf Kaiser

1 reference

13 September 2017

3

Hauke Walter

1 reference

13 September 2017

1

Saleta Sierra

1 reference

13 September 2017

Nadine Lübke

2

1 reference

13 September 2017

Eugen Schülter

4

1 reference

13 September 2017

Stefan Reuter

5

1 reference

13 September 2017

Markus Bickel

7

1 reference

13 September 2017

Hugo da Silva

8

1 reference

13 September 2017

Stefan Esser

10

1 reference

13 September 2017

SnoB-Study group

11

1 reference

13 September 2017

publication date

8 April 2011

1 reference

Medical Microbiology and Immunology

13 September 2017

published in

1 reference

13 September 2017

volume

200

1 reference

13 September 2017

issue

4

1 reference

13 September 2017

page(s)

225-232

1 reference

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00430-011-0194-1

The challenge of HIV-1 subtype diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-011-0194-1

Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-011-0194-1

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-011-0194-1

Evolution of raltegravir resistance during therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-011-0194-1

Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-011-0194-1

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-011-0194-1

Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-011-0194-1

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-011-0194-1

Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance

21 January 2018

1 reference

12 December 2020

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

1 reference

12 December 2020

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

1 reference

12 December 2020

Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus

1 reference

12 December 2020

Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors

1 reference

12 December 2020

10.1007/S00430-011-0194-1

Identifiers

DOI

1 reference

13 September 2017

1 reference